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THE STUDY In terms of design the objective was to determine the safety, 
feasibility and efficacy of TGC. My problems with this are that with a 
nursing staffing ration of 6:1 patients, the feasibility of use in this 
setting has not really been tested because as the authors state - that 
the protocol was followed due to the presence of a dedicated trialist 
clinician; so it does not adress use in the real world, that is 
suggested aim in the objective. They summarise in the discussion 
that TGC was 'feasible' in the AMU. I suggest that hourly BG 
measurements for the infusion period and subsequent dose 
adjustment adds a significant work for the nursing staff and 
pain/inconvenience for the patient, for questionable benefit. This was 
not fully addressed.  
 
One aspect of the methods not described is that the protocol of 
insulin use is not provided.  
 
The testing of blood glucose in the trial was capilliary blood method. 
There are documented problems in reliability in this method that is 
well documented in the ICU literature (Kanji et al Crit CAre Med 33 
804-10 2005). They found that this method was unreliable especially 
in the hypoglycaemic range and advised not to use it. Since much of 
the concept of the current study has been adopted from the crit care 
literature, one is left thinking what evidence there is that this is a 
reliable and reproducable method in this patient group. 
RESULTS & CONCLUSIONS The message from the trial is ok but the authors rightly highlight that 
in the critical care field the evidence has moved away from TGC. 
They state under Article summary that in light of this AMUs should 
expore alternative strategies for BG control in COPD, somewhat 
undermining the relevance of their work. If this is not a concept 
worth pursuing in the AMU, is this study very relevent?  
 
I would like to see the following results included. Number of BG tests 
in each phase. Number and % of patients who experienced a severe 
hypoglycaemic episodes - as this is the main headline safety result 
in the critical care literature and this result should be compared with 
the Van den Burghe and NICE-Sugar studies. 
GENERAL COMMENTS I do have concerns that this research shows that TGC can be 
implemented in an AMU, albeit with a dedicated researcher present. 
It adds to the burden on staff with many additional BG 
measurements and adds to the discomfort of the patient. What is 
missing is any data that this is a worthwhile treatment for these 
patients. Do they benefit from this? To my way of thinking this is the 
1st question to be answered, if they do not then the relevance of this 
work on practice is limited. Following on from this, if the initial 
efficacy data is not present in this patient group, then one could 
argue that this study is less relevent for practitioners (ie it will not 
change practice) so arguably should be published in a less high 
profile journal.  
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REPORTING & ETHICS It is not stated whether ethics approval was granted or not. 
GENERAL COMMENTS Did you consider formal hypothesis tests to compare your results 
with published data presented in table 3? it might give readers better 
understanding of differences/similarities in the data   
 
VERSION 1 – AUTHOR RESPONSE 
Response to comments  
 
From the Managing Editor, BMJ Open  
Please confirm (if this is the case) in the contributorship statement that all authors approved the final 
submitted version.  
All authors approved the final submitted version of the manuscript. This has been added under the 
contributorship statement p 25  
 
Reviewer: Dr Rob Shulman  
In terms of design the objective was to determine the safety, feasibility and efficacy of TGC. My 
problems with this are that with a nursing staffing ration of 6:1 patients, the feasibility of use in this 
setting has not really been tested because as the authors state - that the protocol was followed due to 
the presence of a dedicated trialist clinician; so it does not address use in the real world, that is 
suggested aim in the objective. They summarise in the discussion that TGC was 'feasible' in the AMU. 
I suggest that hourly BG measurements for the infusion period and subsequent dose adjustment adds 
a significant work for the nursing staff and pain/inconvenience for the patient, for questionable benefit. 
This was not fully addressed.  
 
A trial physician was on the wards for patient set up and was available Mon to Fri 9-5pm. Outside 
these hours ward nurses did all the work but telephone support was available. Their excellent protocol 
adherence (p 20) indicates that they were able to do this as part of their workload. We were 
concerned about potential patient discomfort, but only 2 out of 14 who completed an acceptability 
questionnaire were unhappy with the number of finger pricks required and most patients found the 
study acceptable and would have been prepared to go through the same procedures again (p 21).  
 
One aspect of the methods not described is that the protocol of insulin use is not provided.  
We have now uploaded our protocol and recording sheets as supplementary data  
 
The testing of blood glucose in the trial was capillary blood method. There are documented problems 
in reliability in this method that is well documented in the ICU literature (Kanji et al Crit CAre Med 33 
804-10 2005). They found that this method was unreliable especially in the hypoglycaemic range and 
advised not to use it. Since much of the concept of the current study has been adopted from the 
critical care literature, one is left thinking what evidence there is that this is a reliable and reproducible 
method in this patient group.  
We acknowledge that capillary glucose can underestimate hypoglycaemia in critical illness. However 
capillary blood is widely used for blood glucose monitoring on hospital wards in diabetic patients on 
insulin, including those on sliding scales and those admitted with hypoglycaemia. Arterial blood 
glucose monitoring is not possible in patients on acute wards as arterial lines cannot be inserted in 
this setting. It is possible that we underestimated hypoglycaemia in this study and have made a 
statement to this effect in the discussion (p22, reference 23). However as our conclusion is that the 
risk of hypoglycaemia from tight glycaemic control is at least as great in acute wards as it is on 
intensive care, this doesn’t alter our overall message, that alternative strategies should be explored. 
The last sentences of our abstract (p2) and discussion (p 24) have been altered to strengthen this 
conclusion.  
 
The message from the trial is ok but the authors rightly highlight that in the critical care field the 
evidence has moved away from TGC. They state under Article summary that in light of this AMUs 
should expore alternative strategies for BG control in COPD, somewhat undermining the relevance of 
their work. If this is not a concept worth pursuing in the AMU, is this study very relevent?  
 
This work is part of a larger programme towards improving outcomes for COPD exacerbations. This 
programme has:  
 
1. Shown an association between acute hyperglycaemia and poor outcomes in COPD [1]  
2. Identified mechanisms whereby acute hyperglycaemia could drive poor outcomes in COPD [2,3,4]  
3. Established that insulin has anti-inflammatory actions in COPD4  
4. Tested the safety and tolerability of insulin in the acute situation for COPD patients (this study, 
ISRCTN 42412334, UKCLRN 5689).  
5. Identified metformin as a preferable alternative to insulin for blood glucose control in acute 
exacerbations and shown in a retrospective study that COPD patients taking metformin had longer 
survival following hospitalisation for exacerbation than those without (submitted to Thorax 2011, 
outcome awaited)  
6. Commenced a randomised, placebo controlled trial to determine the tolerability, safety and efficacy 
of metformin for acute COPD exacerbations, funded by the British Lung Foundation and adopted by 
the NIHR portfolio (UKCLRN 10063, ISRCTN 66148745)  
 
The study described in this paper is a key step in this research programme. We demonstrated that we 
could perform tight glycaemic control in patients with COPD exacerbations with similar safety and 
efficacy to that achieved on ICU. However just as we completed the study, NICE Sugar was published 
which showed increased mortality in patients undergoing tight glycaemic control with insulin on ICU. 
We therefore looked for an alternative strategy for glycaemic control in COPD. Although we do not 
plan to take the insulin work forward, we feel that it should be published as it provides information 
about glycaemic control in COPD patients on steroids, as well as around feasibility and acceptability 
of clinical trials in acutely unwell inpatients.  
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I would like to see the following results included.  
Number of BG tests in each phase.  
On page 15 this has been added to table 2 (IV 617, SC 494)  
 
Number and % of patients who experienced a severe hypoglycaemic episodes - as this is the main 
headline safety result in the critical care literature and this result should be compared with the Van 
den Burghe and NICE-Sugar studies.  
2 patients each had one episode where capillary glucose was <2.2mM. In the Van den Berghe and 
NICE Sugar studies, 5% and 6.8% patients respectively on intensive insulin therapy experienced 
severe hypoglycaemia. We have now added this statement to results (p19) and added NICE sugar as 
reference 20.  
 
I do have concerns that this research shows that TGC can be implemented in an AMU, albeit with a 
dedicated researcher present. It adds to the burden on staff with many additional BG measurements 
and adds to the discomfort of the patient. What is missing is any data that this is a worthwhile 
treatment for these patients. Do they benefit from this? To my way of thinking this is the 1st question 
to be answered, if they do not then the relevance of this work on practice is limited. Following on from 
this, if the initial efficacy data is not present in this patient group, then one could argue that this study 
is less relevent for practitioners (ie it will not change practice) so arguably should be published in a 
less high profile journal.  
These points have been addressed above  
 
Reviewer: Steven Lane  
 
It is not stated whether ethics approval was granted or not.  
This is stated in the first paragraph of methods, page 6  
 
Did you consider formal hypothesis tests to compare your results with published data  
We considered doing this using a metaanalysis type approach. However due to relatively small 
numbers both of comparator studies and of patients in our study and differences in study design we 
felt that formal hypothesis testing would not add much to the visual presentation of the data.  
 
VERSION 2 - REVIEW 
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THE STUDY I would ask the authors to look again at the incidence of 
hypoglcaemia that they compare in the literature. The key study 
below in medical patients (so broadly similar to their cohort) reported 
an incidense of severe hypoglycaemia of 18.7% of patients in the 
TGC group; The authors quote the incidense from the van den 
bergue surgical study which is less relevent.  
Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin 
therapy in the  
medical ICU. N Engl J Med 2006;354:449-61. 
 
VERSION 2 – AUTHOR RESPONSE 
Many thanks for your email  
In response to Dr Shulman's remaining comment above we have amended our statement on page 19 
to reference the medical ICU study rather than the surgical ICU study as per the attached document  
 
The statement now reads  
2 (10%) patients each had one episode where capillary glucose was <2.2mM. In single centre [20] 
and multicentre [21] intensive insulin trials, 18.7% and 6.8% patients respectively on intensive insulin 
therapy experienced severe hypoglycaemia.  
 
Many thanks for your consideration  
BW  
Emma Baker  
On behalf of the authors  
 
The new reference is  
20. Van den Berghe G, Wilmer A, Hermans G et al. Intensive insulin therapy in the medical ICU. N 
Engl J Med. 2006;354:449-61. 
